




We read with interest the excellent review of
Escherichia coli native valve endocarditis by Micol
et al. [1] . As a group, Enterobacteriaceae are the
most frequent bacterial isolates recovered from
both inpatients and outpatient clinical specimens,
but in the past few years, following increased use
of invasive devices and broad-spectrum antibiot-
ics, E. coli has become less prevalent than Gram-
positive cocci as a cause of nosocomial infection.
However, E. coli remains the most common cause
of nosocomial bacteraemia, usually secondary to
urinary tract infections or respiratory disease.
To supplement the review of Micol et al. [1],
we would like to describe a probable case of
pacemaker-related endocarditis caused by E. coli
following intestinal infection.
A female aged 77 years was admitted to hospital
because of diarrhoea. She had received a definitive
VDD pacemaker because of complete block 1 year
previously, but was otherwise healthy. Her clinical
condition deteriorated, with septic shock necessi-
tating admission to the intensive care unit. E. coli
was isolated from blood cultures, with MICs
(mg ⁄L) of 4 for amoxycillin, <1 for cefotaxime
and <0.25 for ciprofloxacin and ofloxacin. Two
days after commencing treatment with cefotaxime
(2 g ⁄ 6 h), the patient developed fever and anae-
mia. Echocardiography showed images suggest-
ing vegetations attached to the pacemaker lead,
and the pacemaker was therefore exchanged
surgically. Culture of the lead in thioglycolate
broth at 35C for 48 h, and then on Columbia agar
supplemented with sheep blood 5% v ⁄v (Becton
Dickinson BBL, Cockeysville, MD, USA) and
chocolate agar (Becton Dickinson) at 37C, both
in a CO2 10% v ⁄ v enriched atmosphere, yielded
no growth. Treatment with cefotaxime plus
gentamicin for 3 weeks resulted in sterile cultures,
resolution of fever and recovery from anaemia.
The ability of a bacterium to cause infective
endocarditis depends (in addition to its virulence)
on its capacity for adherence to the damaged
endocardial surface. E. coli is often isolated from
cases of bacteraemia, but rarely from cases of
endocarditis, as it is not readily adherent. Two
populations who have been reported to be at risk
for Gram-negative endocarditis are injecting drug-
users and patients with prosthetic valves [2], but
there are no previous reports of cases involving
foreign bodies such as pacemaker leads. Infections
involving implantable electrophysiological car-
diac devices occur at rates of 1–7% [3], but the
majority of such infections are caused by staphy-
lococci. The case described above fulfilled the
modified Duke criteria for diagnosis of infective
endocarditis [4], but was associated with a gastro-
intestinal infection rather than a urinary tract
infection as described by Micol et al. [1]. Although
a single case does not allow significant conclu-
sions, the possibility of such complications in
association with endovascular devices should be
considered, especially in elderly patients.
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What is the place of teicoplanin and
linezolid in the treatment of prosthetic joint
infections?
10.1111/j.1469-0691.2006.01560.x
We read with great interest the recent excellent
review in CMI concerning the management of
infections of osteoarticular prostheses [1]. The
management of prosthetic joint infection has
never been standardised, and this topic suffers
from a lack of scientific evidence concerning
many aspects; however, there are two points on
which we do not fully agree with the author.
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